TY - JOUR
T1 - Lipid metabolism in dialysis patients - The story gets more complicated
AU - Ponda, Manish P.
AU - Barash, Irina
PY - 2008/9
Y1 - 2008/9
N2 - Cardiovascular disease continues to be the foremost cause of morbidity and mortality in dialysis patients. Compared with the general population, dialysis patients suffer from an accelerated disease course that is, at least in part, resistant to conventional therapy. While there are a myriad of potential explanations for this resistance, derangements in lipid metabolism probably play an important role. Here, we discuss the significance of altered lipid metabolism in uremia, such as oxidative lipoprotein modification and the pathophysiology of adipose tissue; limitations of conventional approaches to dyslipidemia such as statin therapy and traditional lipid profiles; and areas of investigation with potential for new therapy, such as reverse cholesterol transport.
AB - Cardiovascular disease continues to be the foremost cause of morbidity and mortality in dialysis patients. Compared with the general population, dialysis patients suffer from an accelerated disease course that is, at least in part, resistant to conventional therapy. While there are a myriad of potential explanations for this resistance, derangements in lipid metabolism probably play an important role. Here, we discuss the significance of altered lipid metabolism in uremia, such as oxidative lipoprotein modification and the pathophysiology of adipose tissue; limitations of conventional approaches to dyslipidemia such as statin therapy and traditional lipid profiles; and areas of investigation with potential for new therapy, such as reverse cholesterol transport.
UR - https://www.scopus.com/pages/publications/54749155576
U2 - 10.1111/j.1525-139X.2008.00470.x
DO - 10.1111/j.1525-139X.2008.00470.x
M3 - Article
C2 - 18764791
AN - SCOPUS:54749155576
SN - 0894-0959
VL - 21
SP - 390
EP - 394
JO - Seminars in Dialysis
JF - Seminars in Dialysis
IS - 5
ER -